CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to SGMO

CERE-120: Adeno-Associated Virus Delivery of Neurturin

Phase 2
Sangamo Therapeutics, Inc. (SGMO)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Idiopathic Parkinson's Disease

View Full Landscape
Drug Information

Target Indication

Idiopathic Parkinson's Disease

Clinical Trial

NCT00985517

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.